Clinical trial
A Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms
NCT07629726 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 31, 2026
- Completion date
- October 31, 2027
- Enrollment
- 72 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.